OncoTherapy Science Competitors and Similar CompaniesClear all
Immutep's competitors and similar companies include Acrivon.
 Immutep Immutep (formerly Prima BioMed) is a biotechnology company focused on developing autoimmune and cancer immunotherapy treatment. |  Acrivon Acrivon (also known as Acrivon Therapeutics) is a clinical-stage oncology company that leverages a precision medicine platform called Acrivon Predictive Precision Proteomics (AP3) for the development of a drug pipeline. | |
Founding Date | Founding Date 2001 | Founding Date 2018 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations Sydney, AU HQ Sydney, AU The Rocks, AU Orsay, FR Berlin, DE Leipzig, DE | Locations Watertown, US HQ Lund, SE |
Employees | Employees 2427% decrease | Employees 415% increase |
Valuation ($) | Valuation ($) 282.4 m | Valuation ($) 256.1 m |
Financial | ||
Net income | Net income ($61.4m) (FY, 2025) | Net income ($77.9m) (FY, 2025) |
For sources of this data, please see the company profile
View Company Profiles
Acrivon
HQ
Watertown, US
Employees
41↑ 5% increase
Acrivon (also known as Acrivon Therapeutics) is a clinical-stage oncology company that leverages a precision medicine platform called Acrivon Predictive Precision Proteomics (AP3) for the development of a drug pipeline.
View company